Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

  • Revenue in USD (TTM)269.40m
  • Net income in USD-929.79m
  • Incorporated1998
  • Employees627.00
  • Location
    MorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
  • Phone+49 89899270
  • Fax+49 8 989927222
  • Websitehttps://www.morphosys.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
bluebird bio Inc5.14m-431.14m684.44m518.00--3.47--133.13-5.77-6.960.0691.920.0055----9,924.71-46.37-31.45-58.80-34.64-167.1955.94-8,386.25-2,856.88---258.800.00-----9.86-0.282---3.88--
Seres Therapeutics Inc13.37m-231.36m685.25m333.00--10.12--51.24-2.35-2.350.13410.54320.0378----40,162.16-65.34-37.60-87.02-47.14-----1,729.94-151.39---82.800.4294--336.3346.1126.42---14.95--
Poseida Therapeutics Inc151.68m-29.22m690.17m304.00--3.19--4.55-0.6727-0.67272.292.520.4722----576,726.30-9.10-54.94-10.40-63.47-----19.26-1,184.41---6.780.2119----26.183.70--7.80--
Emergent Biosolutions Inc1.51bn53.50m696.94m2.42k17.030.4813.620.46050.82030.820329.6629.040.5241.516.26626,407.301.856.992.087.8454.5962.503.5412.622.136.310.42090.0015.2629.68-24.3229.8624.16--
Viking Therapeutics Inc0.00-61.66m697.87m17.00--4.61-----0.7993-0.79930.001.970.00----0.00-31.53-16.66-33.72-17.37------------0.00-------39.23------
Mersana Therapeutics Inc11.90m-208.27m700.41m169.00--7.67--58.84-2.43-2.430.13790.91530.0447----70,437.87-78.23-52.20-104.23-70.47-----1,749.59-547.25---89.590.216---94.81-72.04-93.15---9.78--
Protagonist Therapeutics Inc35.20m-130.11m705.01m122.00--2.89--20.03-2.67-2.670.72174.950.1074--13.73298,288.10-39.71-34.36-44.91-41.35-----369.64-321.60----0.00---4.44---89.80--23.77--
Morphosys Ag (ADR)269.40m-929.79m709.59m627.00------2.63-6.81-6.811.97-0.68060.08712.022.92368,037.80-30.05---33.50--82.88---345.13--3.67-8.871.35---45.19---625.55------
CTI BioPharma Corp32.87m-112.32m714.41m121.00------21.74-1.09-1.090.3074-0.13270.2925----271,611.60-99.98-82.10-169.44-126.5592.86---341.77-475.653.22-9.391.18-------86.67------
Theravance Biopharma Inc51.64m-82.19m717.45m158.00--1.49--13.89-1.1011.250.68627.130.0885--3.67326,854.40-14.09-50.90-17.15-62.74-----159.16-439.62----0.00---23.032.6028.27--9.79--
CymaBay Therapeutics Inc0.00-105.91m724.02m60.00--12.03-----1.25-1.250.000.71060.00----0.00-75.07-45.17-82.20-49.89-------3,438.97---8.000.5888-------76.52--15.68--
Agenus Inc89.90m-214.70m727.73m441.00------8.09-0.7998-0.79980.3333-0.06910.2075--5.88203,854.90-51.73-63.37-82.84-123.7195.82---249.34-98.76---3.088.30--235.3467.2886.67--21.98--
Dyne Therapeutics Inc0.00-181.06m729.78m115.00--2.91-----3.51-3.510.004.810.00----0.00-47.24---50.30--------------0.00-------151.18------
AnaptysBio Inc4.49m-134.85m732.97m102.00--2.63--163.24-4.83-4.830.16079.790.0086--4.6344,019.61-25.86-13.06-26.95-13.71-----3,003.32-165.53----0.00---15.7730.51-189.98--93.77--
Merus NV45.63m-63.64m732.97m121.00--2.45--16.06-1.45-1.451.056.450.1184--15.56377,099.20-16.51-24.71-20.04-29.16-----139.48-178.24----0.00--64.0077.6421.86--9.66--
Amneal Pharmaceuticals Inc2.14bn-132.03m737.73m7.00k--2.48--0.3448-0.8749-0.874914.220.980.54522.593.40305,634.40-6.86-7.97-8.42-9.9335.6934.39-12.59-15.901.071.030.9282--5.0820.49156.09---0.0996--
Data as of Feb 03 2023. Currency figures normalised to MorphoSys AG's reporting currency: US Dollar USD

Institutional shareholders

2.03%Per cent of shares held by top holders
HolderShares% Held
Millennium Management LLCas of 30 Sep 2022953.51k0.70%
Hudson Bay Capital Management LPas of 30 Sep 2022840.00k0.61%
Alphacentric Advisors LLCas of 30 Sep 2022185.00k0.14%
LifeSci Fund Management LLCas of 30 Sep 2022185.00k0.14%
Morgan Stanley & Co. LLCas of 30 Sep 2022160.43k0.12%
Fidelity Management & Research Co. LLCas of 30 Sep 2022131.23k0.10%
Opaleye Management, Inc.as of 30 Sep 2022121.02k0.09%
Tekla Capital Management LLCas of 30 Sep 202281.87k0.06%
Endurant Capital Management LPas of 30 Sep 202268.29k0.05%
Candriam Belgium SAas of 30 Sep 202258.17k0.04%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.